Cyrano Therapeutics Raises $12.8 Million to Complete Phase 2 Trial of CYR-064 for the Restoration of Chronic Smell and Flavor Loss

Currently no FDA-approved therapy for this serious condition afflicting over 15 million in the U.S., with prevalence expected to grow dramatically as a consequence of COVID-19 WASHINGTON, Dec. 10, 2020 -- (Healthcare Sales & Marketing Network) -- Cyran... Regenerative Medicine, Venture Capital, Personnel Cyrano Therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news